COMMUNIQUÉS West-GlobeNewswire

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12
06/11/2024
Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m. ET IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp . (Nasdaq: OCX), a diagnostics technology company, announced [...]
Viemed Healthcare Announces Third Quarter 2024 Financial Results
06/11/2024
LAFAYETTE, La., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced [...]
Monthly information on share capital and company voting rights
06/11/2024
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
06/11/2024
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 06 nov. 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
BrightSpring Health Services Announces CareMed Was Selected as a National Specialty Pharmacy Partner for Leqembi®
06/11/2024
LOUISVILLE, Ky., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud that CareMed, a BrightSpring company and leading independent [...]
Surrozen to Present at Upcoming Healthcare Investor Conferences
06/11/2024
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue [...]
DBV Technologies Reports Third Quarter 2024 Financial Results
06/11/2024
Châtillon, France, November 6, 2024 DBV Technologies Reports Third Quarter 2024 Financial Results DBV closes Q3 2024 with a cash balance of $46.4 million; cash runway into Q1 2025 DBV Technologies (Euronext: DBV – ISIN [...]
DBV Technologies publie ses résultats financiers du troisième trimestre 2024
06/11/2024
Châtillon, France, le 6 novembre (22 :30 CET) 2024 DBV Technologies publie ses résultats financiers du troisième trimestre 2024 DBV clôture le troisième trimestre 2024 avec un solde de trésorerie de 46,4 $ millions [...]
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
06/11/2024
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients [...]
Amedisys Reports Third Quarter 2024 Financial Results
06/11/2024
BATON ROUGE, La., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2024. Three-Month Periods Ended September [...]
STERIS Announces Financial Results for Fiscal 2025 Second Quarter
06/11/2024
Total revenue from continuing operations increased 7%; constant currency organic revenue grew 7% As reported diluted EPS from continuing operations increased to $1.51; adjusted EPS increased to $2.14 Fiscal 2025 outlook [...]
Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
06/11/2024
DEER PARK, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
06/11/2024
Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to SCYNEXIS, received in [...]
MacroGenics to Participate in Upcoming Investor Conferences
06/11/2024
ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics [...]
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma
06/11/2024
Company implementing 42% reduction in force and resizing its Board of Directors to six seats from ten SAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision [...]
Certara Reports Third Quarter 2024 Financial Results
06/11/2024
Updates Full Year 2024 Financial Guidance RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the [...]
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
06/11/2024
Multiple clinical trial milestones were achieved, including encouraging topline data for a Phase 2 trial in CCM, the first patient dosed for a Phase 2 trial in recurrent C. difficile infection, and IND clearance for a [...]
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
06/11/2024
Reports Q3 2024 Total Revenues of $ 128.7 Million, Representing a 25.3 % YoY Increase Record Revenues Driven by Continued Organic Growth in its Rare Disease Franchise Robust Financial Performance Highlights Operational [...]
Pennant Reports Third Quarter 2024 Results
06/11/2024
Conference Call and Webcast scheduled for tomorrow, November 7, 2024 at 10:00 am MT EAGLE, Idaho, Nov. 06, 2024 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of [...]

Pages